Physician profile
Maricar Rellora
NPI 1518632074
$661.88
in general payments reported to CMS, 2019-2025
11 companies · $39.95 in 2025
The $39.95 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.38 · 2023: $189 · 2024: $413 · 2025: $39.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.58 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $173.62 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $34.93 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $27.42 | 2024 | Voquezna |
| Lilly USA, LLC | $24.68 | 2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $24.18 | 2023 | |
| Merck Sharp & Dohme LLC | $21.23 | 2025 | Capvaxive, Gardasil 9 |
| Hologic Sales and Service, LLC | $20.38 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.72 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $16.67 | 2024 | Arexvy, Shingrix |
| Alnylam Pharmaceuticals INC. | $16.47 | 2024 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maricar Rellora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.